Study: Cordis Corp.'s TrapEase vena cava filter shows high fracture rate

November 30, 2011 by MassDevice staff

Concerns about broken vena cava filters resurface as a Japanese study finds a high rate of fracture for Cordis Corp.'s TrapEase permanent implant.

Cordis TrapEase permanent vena cava filter

TrapEase permanent vena cava filter

A new study reported a high fracture rate among permanent inferior vena cava filters made by Cordis Corp., a device-making arm of Johnson & Johnson (NYSE:JNJ).

In a Japanese study of 20 patients with Cordis' TrapEase IVC filter, the devices fractured in half the patients at 50 months.

The study adds to concerns that surfaced last year when the FDA recommended that physicians consider removing retrievable inferior vena cava filters after logging 921 reports of "adverse events" related to the devices.

Sign up to get our free newsletters delivered straight to your inbox

The federal watchdog agency warned that certain IVC filters could fracture, causing pieces of the device to travel through the bloodstream to other parts of the body.

Doctors place the device in the inferior vena cava, the main vein that brings blood back to the heart from the lower half of the body, to keep blood clots from traveling to the lungs and causing pulmonary embolisms. The implant treats patients with venous thromboembolism who have not responded to or cannot take anti-clotting medications.